Ulrike Nitz

3PUBLICATIONS
38CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

|Nov 03, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.

Monika Graeser, Oleg Gluz, Peter Schmid

|Nov 28, 2022
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.

Monika Graeser, Oleg Gluz, Claudia Biehl

Pageof 1

Frequent Collaborators

3 joint publications

Oleg Gluz

3 joint publications

Matthias Christgen

3 joint publications

Sherko Kuemmel

3 joint publications

Monika K Graeser